BLAINJECTIONINJECTABLEPriority Review
Approved
May 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYBREVANT (amivantamab-vmjw) is a bispecific antibody targeting EGFR and MET, approved as an intravenous injection for patients with non-small cell lung cancer harboring specific molecular alterations. It represents a novel mechanism combining dual-target engagement to overcome resistance mechanisms in advanced cancers.
$0.001BPart D
PeakProduct is at peak commercial maturity with established reimbursement, indicating stable but focused team structure for J&J's oncology franchise.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Johnson & Johnson is hiring 4 roles related to this product
Worked on RYBREVANT at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.